Taking everything into account, IMMP scores 3 out of 10 in our fundamental rating. IMMP was compared to 530 industry peers in the Biotechnology industry. IMMP scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. IMMP is quite expensive at the moment. It does show a decent growth rate.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -24.06% | ||
| ROE | -25.43% | ||
| ROIC | N/A |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 37.66 |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 18.86 | ||
| Quick Ratio | 18.86 |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
3.04
+0.1 (+3.4%)
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 12362.57 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 3.86 | ||
| P/tB | 4.04 | ||
| EV/EBITDA | N/A |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -24.06% | ||
| ROE | -25.43% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | N/A |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | N/A | ||
| Cap/Sales | 1556.13% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 18.86 | ||
| Quick Ratio | 18.86 | ||
| Altman-Z | 37.66 |
ChartMill assigns a fundamental rating of 3 / 10 to IMMP.
ChartMill assigns a valuation rating of 0 / 10 to IMMUTEP LTD-SP ADR (IMMP). This can be considered as Overvalued.
IMMUTEP LTD-SP ADR (IMMP) has a profitability rating of 1 / 10.
The Earnings per Share (EPS) of IMMUTEP LTD-SP ADR (IMMP) is expected to decline by -13.32% in the next year.